Ethical and Practical Issues Associated With the Possibility of Using Controlled Human Infection Trials in Developing a Hepatitis C Virus Vaccine
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissionsoup.com..
Despite the existence of established treatments for hepatitis C virus (HCV), more effective means of preventing infection, such as a vaccine, are arguably needed to help reduce substantial global morbidity and mortality. Given the expected challenges of developing such a vaccine among those at heightened risk of infection, controlled human infection studies seem to be a promising potential approach to HCV vaccine development, but they raise substantial ethical and practical concerns. In this article, we describe some of the challenges related to the possibility of using controlled human infection studies to accelerate HCV vaccine development. The related ethical and practical concerns require further deliberation before such studies are planned and implemented.
| Errataetall: |
CommentIn: Clin Infect Dis. 2020 Dec 31;71(11):2991-2992. - PMID 32448897 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:71 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 71(2020), 11 vom: 31. Dez., Seite 2986-2990 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cox, Andrea [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Challenge studies |
|---|
| Anmerkungen: |
Date Completed 28.04.2021 Date Revised 07.02.2024 published: Print CommentIn: Clin Infect Dis. 2020 Dec 31;71(11):2991-2992. - PMID 32448897 Citation Status MEDLINE |
|---|
| doi: |
10.1093/cid/ciaa640 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM310245036 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM310245036 | ||
| 003 | DE-627 | ||
| 005 | 20240207231919.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciaa640 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1283.xml |
| 035 | |a (DE-627)NLM310245036 | ||
| 035 | |a (NLM)32442262 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cox, Andrea |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ethical and Practical Issues Associated With the Possibility of Using Controlled Human Infection Trials in Developing a Hepatitis C Virus Vaccine |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.04.2021 | ||
| 500 | |a Date Revised 07.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Clin Infect Dis. 2020 Dec 31;71(11):2991-2992. - PMID 32448897 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissionsoup.com. | ||
| 520 | |a Despite the existence of established treatments for hepatitis C virus (HCV), more effective means of preventing infection, such as a vaccine, are arguably needed to help reduce substantial global morbidity and mortality. Given the expected challenges of developing such a vaccine among those at heightened risk of infection, controlled human infection studies seem to be a promising potential approach to HCV vaccine development, but they raise substantial ethical and practical concerns. In this article, we describe some of the challenges related to the possibility of using controlled human infection studies to accelerate HCV vaccine development. The related ethical and practical concerns require further deliberation before such studies are planned and implemented | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a challenge studies | |
| 650 | 4 | |a controlled human infection studies | |
| 650 | 4 | |a ethics | |
| 650 | 4 | |a hepatitis C virus | |
| 650 | 4 | |a vaccines | |
| 650 | 7 | |a Hepatitis C Antibodies |2 NLM | |
| 650 | 7 | |a Viral Hepatitis Vaccines |2 NLM | |
| 700 | 1 | |a Sulkowski, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Sugarman, Jeremy |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 71(2020), 11 vom: 31. Dez., Seite 2986-2990 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:71 |g year:2020 |g number:11 |g day:31 |g month:12 |g pages:2986-2990 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciaa640 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 71 |j 2020 |e 11 |b 31 |c 12 |h 2986-2990 | ||